Media stories about PharMerica (NYSE:PMC) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PharMerica earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned media stories about the company an impact score of 15 out of 100, indicating that recent news coverage is very unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Head to Head Review: Pharmerica Corporation (NYSE:PMC) & Cardinal Health (CAH) (americanbankingnews.com)
- Pharmerica Corporation (NYSE:PMC) Receives Consensus Rating of “Hold” from Brokerages (overnewsmagazine.com)
- Pharmerica Corporation (NYSE:PMC) Lowered to “Overweight” at KeyCorp (americanbankingnews.com)
- Research Analysts Offer Predictions for Pharmerica Corporation’s Q4 2018 Earnings (PMC) (americanbankingnews.com)
- Pharmerica Corporation (PMC) Cut to “Neutral” at Credit Suisse Group (americanbankingnews.com)
Shares of PharMerica (PMC) traded down 0.17% on Friday, reaching $29.05. The company’s stock had a trading volume of 346,427 shares. The company has a market cap of $904.07 million, a PE ratio of 39.36 and a beta of 0.92. PharMerica has a 52-week low of $19.20 and a 52-week high of $29.10. The firm has a 50 day moving average of $26.64 and a 200 day moving average of $24.94.
PharMerica (NYSE:PMC) last issued its earnings results on Wednesday, August 2nd. The company reported $0.47 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.47. The business had revenue of $592 million during the quarter, compared to analysts’ expectations of $592.96 million. PharMerica had a net margin of 0.79% and a return on equity of 3.41%. The business’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.47 earnings per share. Analysts predict that PharMerica will post $1.92 earnings per share for the current year.
Several equities analysts have commented on the company. UBS AG reaffirmed a “neutral” rating and issued a $29.25 price target (up previously from $26.00) on shares of PharMerica in a report on Thursday, August 3rd. KeyCorp lowered PharMerica to an “overweight” rating in a research note on Wednesday, August 2nd. BidaskClub lowered PharMerica from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Barrington Research lowered PharMerica from an “outperform” rating to an “underperform” rating in a research note on Thursday, August 3rd. Finally, Credit Suisse Group lowered PharMerica from an “outperform” rating to a “neutral” rating and increased their price target for the stock from $29.00 to $29.25 in a research report on Friday, August 4th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $28.83.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Very Unlikely to Affect PharMerica (PMC) Stock Price” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.com-unik.info/2017/08/11/somewhat-favorable-media-coverage-very-unlikely-to-impact-pharmerica-corporation-pmc-stock-price-updated-updated-updated.html.
What are top analysts saying about PharMerica Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PharMerica Co. and related companies.